Published in final edited form as:

J Allergy Clin Immunol Pract. 2017 ; 5(3): 737–743.e3. doi:10.1016/j.jaip.2016.12.006.

Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Healthcare System

Kimberly G. Blumenthal, MD^{a,b,c,d,*}, Kenneth H. Lai, MA^{e,*}, Mingshu Huang, PhD, MA^f, Zachary S. Wallace, MD^{a,c}, Paige G. Wickner, MD, MPH^{c,g}, and Li Zhou, MD, PhD^{c,h,i}

^aDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

^bMedical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

^cHarvard Medical School, Boston, Massachusetts, USA

^dEdward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital, Boston, Massachusetts, USA

^ePartners HealthCare System, Boston, Massachusetts, USA

^fBiostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA

^gDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA

^hPartners eCare, Partners HealthCare System, Boston, Massachusetts, USA

ⁱDivision of General Internal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA

Corresponding Author: Kimberly G. Blumenthal, Division of Rheumatology, Allergy and Immunology, Medical Practice Evaluation Center, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, MA 02114, USA, Phone: +1(617) 726-5405, kblumenthal1@partners.org.

*These authors contributed equally

Prior Presentation: "Reported Incidence of Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs in the Electronic Health Record," Featured Poster Session *Unleashing the Power of Health Information Technology*, American Academy of Allergy, Asthma and Immunology Annual Meeting, March 6, 2016 (Los Angeles, California).

Conflicts of interest: None

Author's Contributions: KGB, KHL, PGW and LZ designed the study.

KHL performed data abstraction.

KGB and MH assisted with statistical analysis.

KGB, KHL, ZSW, PGW, MH and LZ analyzed and interpreted the results.

KGB drafted the first report.

KGB, KHL, ZSW, PGW, MH and LZ assisted with interpretation and revision of the report.

KGB and LZ obtained funding.

LZ provided supervision and administrative support.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Abstract

Background—Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequently used medications in the United States. NSAID use can be limited by adverse drug reactions (ADRs), including hypersensitivity reactions (HSRs).

Objective—We aimed to use electronic health record (EHR) data to determine the incidence and predictors of HSRs to prescription NSAIDs.

Methods—We performed a retrospective cohort study of all adult outpatients in a large healthcare system prescribed diclofenac, indomethacin, nabumetone, or piroxicam between January 1, 2004 and September 30, 2012. The primary outcome was an ADR or HSR attributed to the prescribed NSAID within one year of prescription, determined from a longitudinal allergy database. We used natural language processing to classify known ADRs as either HSRs or side effects. Multivariable logistic regression models were used to identify independent risk factors for NSAID HSRs.

Results—Of 62,719 patients prescribed NSAIDs, 1,035 (1.7%) had an ADR, of which 189 (18.3%) were HSRs. Multivariable regression analysis identified that patients with prior drug HSR history (OR 1.8 [95% CI 1.3, 2.5]), female sex (OR 1.8 [95% CI 1.3, 2.4]), autoimmune disease (OR 1.7 [95% CI 1.1, 2.7]), and those prescribed the maximum standing NSAID dose (OR 1.5 [95% CI 1.1, 2.0]) had increased odds of NSAID HSR.

Conclusions—NSAIDs therapeutic use can be limited by ADRs; About 1 in 5 NSAID ADRs is an HSR. Both patient and drug factors contribute to HSR risk and are important to guide patient counseling.

Keywords

Adverse reaction; allergy; drug; hypersensitivity; side effect

Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications.¹ NSAIDs can cause a variety of adverse drug reactions (ADRs) that range from minor to severe.²⁻⁴ Reactions to NSAIDs include side effects (e.g., gastrointestinal upset, bleeding, nephrotoxicity)^{1,5} as well as allergic or pseudoallergic reactions (i.e., hypersensitivity reactions [HSRs]).⁵ While some side effect reactions do not preclude future use of NSAIDs, HSRs warrant particular caution, as allergic (i.e., immunoglobulin [Ig] E-mediated) reactions predictably worsen with re-exposure and pseudoallergic reactions often exhibit dose-dependent recurrence.⁶ NSAIDs have been identified as one of the most common causes of drug-induced anaphylactic reactions.^{7,8}

Prior studies suggest a 1.9-3.5% prevalence of self-reported allergy to NSAIDs,⁹⁻¹¹ with two studies finding self-reported incidence ranging from 0.2% to 6.0%.^{10,12} However, these studies have included all “allergies” -- inclusive of both HSRs and side effects -- in their frequency estimates. Additionally, although electronic health records (EHRs) contain both coded and non-coded (i.e., free-text) data, prior incidence estimates of NSAID allergy from EHR data used only coded elements, which may have underestimated HSR burden.

Previously reported risk factors for NSAID HSRs include chronic urticaria/angioedema, prior HSRs, aspirin-exacerbated respiratory disease (AERD), and atopy.^{6,13-18} One study using United States insurance claims data identified that the NSAID indications of acute pain and inflammatory arthritis increased the risk of NSAID HSRs.¹⁹ In the present study, we applied novel informatics methods using EHR data to estimate the incidence of ADRs and HSRs to prescription NSAIDs, and defined risk factors for developing these HSRs.

Methods

Study Design, Population

We performed a retrospective cohort study using the EHR data available within Partners HealthCare System (PHS), an integrated health care delivery network in the Boston area of the United States. In order to identify which NSAIDs to use for this study, we first identified the most common NSAIDs in a cross-sectional analysis of the Partners Enterprise Allergy Repository (PEAR), a database of allergy and adverse effect information that contains over four million active allergy records for over two million PHS patients (Table E1 in the Online Repository).^{11,20} Our analysis focused on NSAIDs that were: (1) prescription-only in the United States, (2) inhibitors of both of the cyclooxygenase 1 and cyclooxygenase 2 (COX-2) enzymes, and (3) used predominantly by the oral route (i.e., PO). Diclofenac, indomethacin, nabumetone, and piroxicam met these criteria and were included in this study.

The study population included all adult outpatients (age ≥ 18 years) prescribed any of the four oral NSAIDs from January 1, 2004 through September 30, 2012, and who had at least one visit within one year at any PHS outpatient clinic after the NSAID prescription.

We subsequently ran a separate analysis of patients prescribed only celecoxib or meloxicam, two selective COX-2 inhibitors.

Primary Outcome

The primary outcome was an ADR or HSR to the prescribed NSAID within one year. We chose to evaluate the fixed time-frame of one year to allow sufficient time for patients to have a repeat visit and report an ADR/HSR. We identified ADRs and HSRs from PEAR, which contained detailed symptoms reported by patients and/or observations made by healthcare providers. PEAR reactions could be entered in a coded format that used a pre-defined list of reactions selected by providers for each drug, or a free-text format, which comprised about 6% of entries. For free-text reaction entries, informatician investigators (KL, LZ) used natural language processing algorithms to automatically map reactions to a standardized form.^{11,21} For example, the free-text reaction “full body hives” was mapped to the coded reaction “hives.” All mapped free-text reactions were manually verified by another investigator (KGB).

We considered all PEAR reaction entries an ADR. We defined HSRs as the subset of ADRs that included reactions mapped to anaphylaxis, hypotension, angioedema, swelling, rhinitis, bronchospasm, asthma, wheezing, shortness of breath, hives, urticaria, itching, or rash.²² We additionally considered non-immediate HSRs previously attributed to NSAIDs by performing key word searches of the PEAR reaction field for serum sickness, drug rash

eosinophilia and systemic symptoms syndrome, erythema multiforme, acute interstitial nephritis, fixed drug eruption, erythema nodosum, Stevens-Johnson syndrome, toxic epidermal necrolysis, pneumonitis, meningitis, lichenoid drug eruptions, and leukocytoclastic vasculitis.^{6,23} Remaining known reactions were considered side effect reactions, which we grouped and sorted by frequency. “Unknown” reactions were considered separately, and could reflect that the patient and/or the provider did not know the reaction details.

Because PEAR allows for drug class entries (e.g, NSAIDs) as well as specific drug entries (e.g., diclofenac), we conducted a sensitivity analysis of ADR and HSR incidence by assuming that all PEAR allergy entries of “NSAID” were related to the NSAID that was prescribed. For this expanded definition, we similarly distinguished HSRs, side effects, and unknown reactions.

We used identical methods to identify incidence of ADRs and HSRs among adult outpatients prescribed only celecoxib or meloxicam from January 1, 2004 through September 30, 2012, and who had at least one visit within one year at any PHS outpatient clinic after the prescription.

Predictor Variables

Age (at the time of first NSAID prescription), gender, and race/ethnicity were identified from EHR demographic tables. We defined ADR and HSR histories using the PEAR database. We identified NSAID treatment indications (e.g., rheumatoid arthritis, joint pain, chronic pain) as a coded or free-text entry into the EHR “Problem List” or presence of the relevant code(s) from the International Classification of Diseases, ninth edition (ICD-9) entered within 30 days of the NSAID prescription. All ICD-9 codes were informed by prior studies, when available (Table E2 in the Online Repository). Patient comorbidities were identified similarly, as either on the patient's “Problem List” or presence of a relevant ICD-9 code before the NSAID prescription date. To search AERD patients, we used key word searches of the reaction field and a previously studied informatics algorithm.²⁴ Using the NSAID electronic prescription, we created a Food and Drug Administration “maximum daily dose” for each NSAID: diclofenac 200 mg/day, indomethacin 150mg/day, nabumetone 2000mg/day, and piroxicam 20 mg/day.²⁵ We used the EHR “Medication List” to define medication-specific covariates, including any previous NSAID prescription (prescriptions for over the counter NSAIDs such as ibuprofen and naproxen, when present, were included) and concomitant medications, defined as an active EHR prescription for the medication (aspirin, opiates, or angiotensin-converting enzyme inhibitors) at the time of NSAID prescription. Classification of drugs into the opiate and angiotensin-converting enzyme inhibitor classes followed the American Hospital Formulary Service Pharmacologic-Therapeutic Classification.^{11,26}

Statistical Analyses

Data are displayed as numbers with frequencies, and medians with inter-quartile ranges. For the primary NSAID cohort, we compared binary variables using Fisher's exact test, non-dichotomous categorical variables using chi-squared test, ordinal variables using the

Cochran-Armitage Trend test, and continuous variables using the Wilcoxon Rank Sum test. To identify NSAID HSR risk factors, we created multivariable logistic regression models for the primary outcome of HSR, first using the standard HSR definition, then using the expanded HSR definition that included NSAID class allergies.

The regression models were built using both *a priori* knowledge and imbalances between groups identified in univariable analyses. We used $p \leq 0.05$ as the screening criterion for each potential covariate not informed by prior knowledge. Our final chosen models included all variables significant at $p < 0.05$ in at least one of the multivariable models. We calculated odds ratios with 95% confidence intervals. P values < 0.05 were considered statistically significant. Statistical analyses were performed in SAS version 9.4 (Cary, NC, USA). This study was approved by the Partners Institutional Review Board.

Results

Incidence and Phenotypes

Of 62,719 patients prescribed oral diclofenac, indomethacin, nabumetone, or piroxicam from January 1, 2004 through September 30, 2012, 1,035 (1.7%) had an ADR (Table I). ADRs included 189 patients (18.3% of ADRs; 0.3% incidence) with HSRs. HSRs included rash (n=72, 38.1%), angioedema or swelling (n=51, 27.0%), urticaria or hives (n=37, 19.6%), itching (n=28, 14.8%), shortness of breath, asthma or wheezing (n=12, 6.3%), and anaphylaxis or hypotension (n=10, 5.3%). We identified only one non-immediate HSR, serum sickness, in one patient. Among 801 patients who experienced side effect reactions, the most common reactions were gastrointestinal upset (n=543, 67.8%), dizziness (n=59, 7.4%), headaches (n=52, 6.5%), mental status change (n=33, 4.1%), and renal toxicity (n=31, 3.9%).

Using the expanded definition of NSAID ADRs/HSRs, incidence of NSAID ADRs was 1.8% and incidence of NSAID HSRs remained 0.3%, or 18.6% of ADRs.

Of 32,215 patients prescribed celecoxib or meloxicam from January 1, 2004 through September 30, 2012, 429 (1.3%) had an ADR, of which 121 (28.2% of ADRs; 0.4% incidence) had an HSR (Table E3). Using the expanded ADR/HSR definition, 616 (1.9%) had an ADR, of which 163 (26.5% of ADRs; 0.5% incidence) were HSRs.

Factors Associated with NSAID HSRs

In univariable analyses, patients who developed an NSAID HSR were more commonly female (Table II). Self reported race/ethnicity was imbalanced between HSR and non-HSR groups; the frequency of Hispanic patients was lower in people experiencing an HSR than those not experiencing one (2.1% vs 5.2%). Patients with an NSAID HSR had a median of 2 more office visits the year after prescription ($p < 0.001$). NSAID HSR patients were more likely to have any ADR history ($p < 0.001$), more prior ADRs ($p < 0.001$), prior NSAID ADRs ($p = 0.03$), any HSR history ($p < 0.001$), more prior HSRs ($p < 0.001$), and prior NSAID HSRs ($p = 0.04$). Patients with an NSAID HSR were more likely to be prescribed the NSAID for rheumatoid arthritis (3.7% vs. 1.6%, $p = 0.03$) and joint pain (15.9% vs. 10.0%, $p = 0.01$). NSAID HSR patients more likely to have autoimmune disease (11.6% vs. 6.1%, $p = 0.003$).

We did not find a relationship between NSAID HSRs and atopy (20.6% vs. 17.0%, $p=0.21$) or chronic urticaria/angioedema (0.5% vs 0.4%, $p=0.50$). One patient with an NSAID HSR was identified with AERD. Patients with an NSAID HSR were more likely to have the maximum NSAID dose prescribed (31.8% vs. 25.0%, $p=0.04$); HSR patients were more likely to have previous exposure to NSAIDs and more prior NSAID prescriptions ($p=0.03$ and $p=0.001$, respectively). Patients with NSAID HSRs were not more likely to have concomitant aspirin, opiate, or angiotensin-converting enzyme inhibitor prescribed.

In multivariable logistic regression analysis, we identified that patients with prior drug HSR history (OR 1.8 [95% CI 1.3, 2.5]), female sex (OR 1.8 [95% CI 1.3, 2.4]), autoimmune disease (OR 1.7 [95% CI 1.1, 2.7]), and prescribed the maximum standing NSAID dose (OR 1.5 [95% CI 1.1, 2.0], Table III) have an increased odds of NSAID HSR. Using the expanded HSR definition led to a similar multivariable model with slightly lower OR estimates for female sex and autoimmune disease, and approximately the same OR estimate for prior drug HSR history. In the expanded model, prescribing the maximum standing NSAID dose lost statistical significance (OR 1.3, 95% CI [1.0, 1.8], $p=0.07$).

Discussion

In this study, we used a large amount of EHR data to identify the reported incidence, reaction types, and risk factors for HSRs to four prescription-only NSAIDs. We found that while most patients tolerate their NSAID prescription, at least 1.7% of patients taking NSAIDs reported an ADR. We used informatics techniques to identify that about one in 5 NSAID ADRs was likely an HSR. Finally, we identified risk factors for NSAID HSRs that can be used to guide patient counseling, including prior drug HSR history, female sex, autoimmune disease, and prescribing the maximum NSAID dose.

Our observed one-year incidence of ADRs was 1.7%, and using an expanded definition, ADR incidence was 1.8%. This estimate falls within the range of previously reported estimates.^{10,12} We found NSAID side effect reactions, including some potentially mild (i.e., gastrointestinal complaints, dizziness, headache) and some potentially severe (e.g., nephrotoxicity) that are similar to prior data.^{1,12,25} Patients prescribed only COX-2 inhibitors had a lower overall one-year ADR incidence using the standard definition (1.3%), although using the expanded definition, incidence was similar (1.9%). For these patients, HSRs comprised a greater proportion of the ADRs (28.2% using the standard definition and 26.5% using the expanded definition). While not evaluated explicitly, this finding might be explained by underlying differences in patients prescribed only COX-2 inhibitors (e.g., patients who have chronic urticaria/angioedema). Many patients who suffer NSAID ADRs and/or HSRs have diagnoses that warrant continued NSAID use, which poses a barrier to optimal medical treatment or presents a conflict with maintaining patient safety. Indeed, NSAIDs are identified as the culprit drug responsible for 1 in 10 ADRs that require hospital admission.^{2,3,5}

In this study, we identified that about 1 in 5 NSAID ADRs was an HSR. Because NSAID use is ubiquitous and increasing both nationally and internationally, awareness of NSAID HSRs is clinically important. While this study is the first to define the proportion of NSAID

ADRs that are HSRs, the composition is similar to prior reported estimates of the general contribution of drug hypersensitivity to adverse drug events.²⁷ Although many patients with HSRs to any NSAID must avoid the entire class of NSAIDs, some patients have an HSR to a specific (i.e., singular) NSAID or group of NSAIDs with a shared chemical structure.¹³ The current schema for categorizing NSAID HSRs includes four types of pseudoallergic reactions (elicited by the enzymatic activity of the cyclooxygenase enzyme) and two allergic reactions (presumed mediated by IgE).^{13,28} Pseudoallergic reactions specifically include asthma and rhinosinusitis (type 1), NSAID-induced urticaria/angioedema in patients with chronic urticaria (type 2), NSAID induced urticaria/angioedema in otherwise asymptomatic patients (type 3), and blended reactions involving mixed respiratory and cutaneous findings (type 4). Allergic reactions include reactions to a single NSAID or group of NSAIDs with similar chemical structure. Among allergic reactions, type 5 is urticaria or angioedema and type 6 is anaphylaxis; however, type 5 and type 6 reactions are thought to be due to the same IgE mechanism with different reaction severity.^{13,28,29} The systematic evaluation and classification of patients with NSAID HSRs can help determine future viability of NSAIDs. However, because of the complexity involved with classification of NSAID HSRs, patients who require aspirin or NSAID treatment who have a prior NSAID HSR may benefit from evaluation by an allergy specialist.^{6,30-34}

We identified female sex as a risk factor for NSAID HSRs, which is consistent with previous EHR-based reports.^{10,19,35} Prior drug allergy data have generally demonstrated that higher doses and longer courses increase risk of HSRs.^{6,10,35} We similarly identified prescribing the maximum NSAID dose was a risk factor for NSAID HSR. This observed “dose-responsiveness” suggests that many of the HSRs were likely pseudoallergic rather than IgE-mediated. Additionally consistent with this hypothesis is that atopy, previously found to be more common in IgE-mediated NSAID allergy, was not a significant predictor in this cohort.¹⁸ One prior study using 11 ICD-9 HSR codes in a United States Medicaid dataset found that rheumatoid arthritis increased odds of NSAID HSR.¹⁹ We similarly found increased frequency of HSR with rheumatoid arthritis in univariable analysis, and autoimmune disease was associated with a 60-70% increased odds of NSAID HSRs in multivariable analysis. Defining the relationship between NSAID HSRs and autoimmune disease is an important area for future prospective study.

Despite the clinical experience of allergists who evaluate patients with NSAID HSRs, we did not find chronic urticaria/angioedema to increase odds of HSR. This could be due to variable clinical documentation of chronic urticaria/angioedema in EHRs or provider awareness that NSAIDs are relatively contraindicated in patients with chronic urticaria/angioedema. While a validated, ICD-9 coding algorithm exists to identify chronic idiopathic urticaria using EHRs, we found only 227 patients (0.4%) with the disease, and only one patient with chronic urticaria/angioedema who developed an NSAID HSR. Although there is a well-defined relationship between nasal and respiratory HSR symptoms and AERD, we found only one case of AERD in this cohort. It is possible that AERD patients were appropriately not prescribed NSAIDs and therefore not represented in this cohort.²⁴ Further studies that assess NSAID prescription patterns among patients with chronic urticaria/angioedema and AERD are required to further understand these findings. Acute pain, while a significant

predictor in the prior claims-based study,¹⁹ was not a predictor in this study; of 118 patients identified in the cohort with acute pain, none developed an HSR.

There are several limitations to this analysis. First, the allergy data we used in this study are not validated; drug and reaction data can be patient-reported and/or clinician-observed. The data varies in quality and many healthcare team members lack drug allergy knowledge to appropriately enter allergy assessments.³⁶⁻³⁸ Attribution of an ADR or HSR may not have been correctly identified, and given the large-scale, retrospective nature of this study, no formal causality assessment (e.g., Naranjo ADR probability scale or World Health Organization causality criteria)³⁹ would have been feasible. However, use of usual clinical care allergy data has benefits; regardless of whether the association between the drug and reaction is true, the patient's EHR report of NSAID allergy will impact future prescribing of all NSAIDs, including aspirin.^{40,41} We chose to evaluate the allergy record at one fixed time period after prescription (one year) because this would allow sufficient time for a patient to visit a doctor in our healthcare system and report an ADR to NSAIDs. However, we still may have missed minor reactions that patients did not remember at their visit or reactions that patients discounted as not important. Because Partners HealthCare is an integrated yet open healthcare system, we were also limited by not knowing patients' complete medications, which could include outside hospital prescriptions and over the counter medications, including other NSAIDs. While we chose to study prescription-only NSAIDs and primarily report ADRs/HSRs to the identically prescribed NSAID (i.e., the standard definition and analysis) to minimize the impact of this issue, all NSAIDs may not have similar propensities to cause ADRs/HSRs.^{19,42} Incidence of ADRs and HSRs may have been higher if we were able to evaluate aspirin, ibuprofen, and/or naproxen, the NSAIDs with the highest prevalence of reported allergy in both the US and the PEAR database.¹¹ Finally, we cannot exclude the possibility of selection bias towards patients that tolerate NSAIDs, since 43% of patients had prior NSAIDs prescribed and presumably tolerated, and 17% of cohort patients were taking and tolerating aspirin.

By examining a large retrospective cohort of outpatients, we find that the 1-year incidence of ADRs to prescription NSAIDs is 1.7-1.8%; 1 in 5 ADRs was an HSR. Patients prescribed COX-2 inhibitors only had a similar incidence of ADRs (1.3-1.9%), although a greater proportion of ADRs were HSRs. Our data identify NSAID HSR risk factors, including prior drug HSR history, female sex, autoimmune disease, and prescribing the maximum NSAID dose. Clinician awareness of NSAID hypersensitivity in patients with these risk factors could guide patient counseling and safe prescribing practices.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Nicholas Pricco, Niki Holtzman, and Yu Li for their research assistance.

Funding: This study was funded by AHRQ R01HS022728. Dr. Blumenthal receives/received support from National Institutes of Health T32 HL116275 and the Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational

Sciences, National Institutes of Health Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.

References

1. Jin J. JAMA PATIENT PAGE. Nonsteroidal Anti-inflammatory Drugs. JAMA. 2015; 314:1084.doi: 10.1001/jama.2015.9936 [PubMed: 26348765]
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *Bmj*. 2004; 329:15–9. DOI: 10.1136/bmj.329.7456.15 [PubMed: 15231615]
3. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. *Br J Clin Pharmacol*. 2007; 63:136–47. DOI: 10.1111/j.1365-2125.2006.02698.x [PubMed: 16803468]
4. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. *Ther Clin Risk Manag*. 2015; 11:1061–75. DOI: 10.2147/TCRM.S79135 [PubMed: 26203254]
5. Alexopoulou A, Dourakis SP, Mantzoukis D, Pitsariotis T, Kandyli A, Deutsch M, et al. Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. *Eur J Intern Med*. 2008; 19:505–10. DOI: 10.1016/j.ejim.2007.06.030 [PubMed: 19013378]
6. Solensky R, Khan D. Drug Allergy: An Updated Practice Parameter. *Annals of Allergy, Asthma and Immunology*. 2010; 105:259–73. DOI: 10.1016/j.anai.2010.08.002
7. van der Klauw MM, Stricker BH, Herings RM, Cost WS, Valkenburg HA, Wilson JH. A population based case-cohort study of drug-induced anaphylaxis. *Br J Clin Pharmacol*. 1993; 35:400–8. DOI: 10.1111/j.1365-2125.1993.tb04157.x [PubMed: 8097922]
8. Faria E, Rodrigues-Cernadas J, Gaspar A, Botelho C, Castro E, Lopes A, et al. Drug-induced anaphylaxis survey in Portuguese Allergy Departments. *J Investig Allergol Clin Immunol*. 2014; 24:40–8.
9. Gomes E, Cardoso MF, Praca F, Gomes L, Marino E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. *Clin Exp Allergy*. 2004; 34:1597–601. DOI: 10.1111/j.1365-2222.2004.02070.x [PubMed: 15479276]
10. Macy E, Ho NJ. Multiple drug intolerance syndrome: prevalence, clinical characteristics, and management. *Ann Allergy Asthma Immunol*. 2012; 108:88–93. DOI: 10.1016/j.anai.2011.11.006 [PubMed: 22289726]
11. Zhou L, Dhopeswarkar N, Blumenthal KG, Goss F, Topaz M, Slight SP, et al. Drug allergies documented in electronic health records of a large healthcare system. *Allergy*. 2016; 71:1305–13. DOI: 10.1111/all.12881 [PubMed: 26970431]
12. Koffeman AR, Van Buul AR, Valkhoff VE, Jong GW, Bindels PJ, Sturkenboom MC, et al. Adverse drug reactions in a primary care population prescribed non-steroidal anti-inflammatory drugs. *Scand J Prim Health Care*. 2015; 33:163–9. DOI: 10.3109/02813432.2015.1067513 [PubMed: 26198810]
13. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. *Ann Allergy Asthma Immunol*. 2001; 87:177–80. DOI: 10.1016/S1081-1206(10)62221-1 [PubMed: 11570612]
14. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, Gonzalez-Aveledo L. Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria. *J Eur Acad Dermatol Venereol*. 2015; 29:698–701. DOI: 10.1111/jdv.12658 [PubMed: 25263736]
15. Sanchez-Borges M, Capriles-Hulett A. Atopy and NSAID sensitivity. *J Allergy Clin Immunol*. 1997; 100:143–4. [PubMed: 9257803]
16. Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. *Ann Allergy Asthma Immunol*. 2000; 84:101–6. DOI: 10.1016/S1081-1206(10)62748-2 [PubMed: 10674573]

17. Asero R. Multiple sensitivity to NSAID. *Allergy*. 2000; 55:893–4. DOI: 10.1034/j.1398-9995.2000.00698.x [PubMed: 11003457]
18. Asero R. Single NSAID hypersensitivity is associated with atopic status. *Eur Ann Allergy Clin Immunol*. 2015; 47:48–53. [PubMed: 25781194]
19. Strom BL, Carson JL, Schinnar R, Sim E, Morse ML. The effect of indication on the risk of hypersensitivity reactions associated with tolmetin sodium vs other nonsteroidal antiinflammatory drugs. *J Rheumatol*. 1988; 15:695–9. [PubMed: 3397980]
20. Kuperman GJ, Marston E, Paterno M, Rogala J, Plaks N, Hanson C, et al. Creating an enterprise-wide allergy repository at Partners HealthCare System. *AMIA Annu Symp Proc*. 2003:376–80. [PubMed: 14728198]
21. Topaz M, Seger DL, Slight SP, Goss F, Lai K, Wickner PG, et al. Rising drug allergy alert overrides in electronic health records: an observational retrospective study of a decade of experience. *J Am Med Inform Assoc*. 2016; 23:601–8. DOI: 10.1093/jamia/ocv143 [PubMed: 26578227]
22. Plasek JM, Goss FR, Lai KH, Lau JJ, Seger DL, Blumenthal KG, et al. Food entries in a large allergy data repository. *J Am Med Inform Assoc*. 2016; 23:e79–87. DOI: 10.1093/jamia/ocv128 [PubMed: 26384406]
23. Blumenthal KG, Wickner PG, Lau JJ, Zhou L. Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional analysis of patients in an integrated allergy repository of a large health care system. *J Allergy Clin Immunol Pract*. 2015; 3:277–80 e1. DOI: 10.1016/j.jaip.2014.10.002 [PubMed: 25609329]
24. Cahill KN, Johns CB, Cui J, Wickner P, Bates DW, Laidlaw TM, et al. Automated identification of an aspirin-exacerbated respiratory disease cohort. *J Allergy Clin Immunol*. 2016; doi: 10.1016/j.jaci.2016.05.048
25. [Accessed October 6, 2016] Micromedex. Truven Health Analytics. 2016. <https://www.micromedexsolutions.com/micromedex2/librarian/CS/C99820/PFActionId/pf.HomePage/ssl/true>
26. Goss FR, Zhou L, Plasek JM, Broverman C, Robinson G, Middleton B, et al. Evaluating standard terminologies for encoding allergy information. *J Am Med Inform Assoc*. 2013; 20:969–79. DOI: 10.1136/amiajnl-2012-000816 [PubMed: 23396542]
27. Kelly WN. Potential risks and prevention, Part 1: Fatal adverse drug events. *Am J Health Syst Pharm*. 2001; 58:1317–24. [PubMed: 11471479]
28. Simon, RA. UptoDate [Internet]. Waltham, MA: Wolters Kluwer; 2015. NSAIDs (including aspirin): Allergic and pseudoallergic reactions. <https://www.uptodate.com/contents/nsaids-including-aspirin-allergic-and-pseudoallergic-reactions> [Accessed October 6, 2016]
29. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. *Allergy*. 2013; 68:1219–32. DOI: 10.1111/all.12260 [PubMed: 24117484]
30. Saff RR, Banerji A. Management of patients with nonaspirin-exacerbated respiratory disease aspirin hypersensitivity reactions. *Allergy Asthma Proc*. 2015; 36:34–9. DOI: 10.2500/aap.2015.36.3800 [PubMed: 25562554]
31. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002; 324:71–86. DOI: 10.1136/bmj.324.7329.71 [PubMed: 11786451]
32. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. *Am J Med*. 2008; 121:43–9. DOI: 10.1016/j.amjmed.2007.10.002 [PubMed: 18187072]
33. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. *Arch Intern Med*. 2012; 172:209–16. DOI: 10.1001/archinternmed.2011.628 [PubMed: 22231610]
34. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998; 97:1837–47. DOI: 10.1161/01.CIR.97.18.1837 [PubMed: 9603539]

35. Macy E, Poon KYT. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. *The American journal of medicine*. 2009; 122:778 e1–7. DOI: 10.1016/j.amjmed.2009.01.034
36. Stukus DR, Green T, Montandon SV, Wada KJ. Deficits in allergy knowledge among physicians at academic medical centers. *Ann Allergy Asthma Immunol*. 2015; 115:51–5 e1. DOI: 10.1016/j.anai.2015.05.001 [PubMed: 26024806]
37. Sturm JM, Temprano J. A survey of physician practice and knowledge of drug allergy at a university medical center. *J Allergy Clin Immunol Pract*. 2014; 2:461–4. DOI: 10.1016/j.jaip.2014.02.004 [PubMed: 25017537]
38. Blumenthal KG, Shenoy ES, Hurwitz S, Varughese CA, Hooper DC, Banerji A. Effect of a drug allergy educational program and antibiotic prescribing guideline on inpatient clinical providers' antibiotic prescribing knowledge. *J Allergy Clin Immunol Pract*. 2014; 2:407–13. DOI: 10.1016/j.jaip.2014.02.003 [PubMed: 25017528]
39. Naranjo CA, Shear NH, Lancot KL. Advances in the diagnosis of adverse drug reactions. *J Clin Pharmacol*. 1992; 32:897–904. DOI: 10.1002/j.1552-4604.1992.tb04635.x [PubMed: 1447396]
40. Leventhal JM, Hutchinson TA, Kramer MS, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. III. Results of tests among clinicians. *JAMA*. 1979; 242:1991–4. DOI: 10.1001/jama.1979.03300180035028 [PubMed: 480646]
41. van Dijk SM, Gardarsdottir H, Wassenberg MW, Oosterheert JJ, de Groot MC, Rockmann H. The High Impact of Penicillin Allergy Registration in Hospitalized Patients. *J Allergy Clin Immunol Pract*. 2016; 4:926–31. DOI: 10.1016/j.jaip.2016.03.009 [PubMed: 27131826]
42. Strom BL, Carson JL, Morse ML, West SL, Soper KA. The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. *Arthritis Rheum*. 1987; 30:1142–8. DOI: 10.1002/art.1780301009 [PubMed: 3314878]

Abbreviations

NSAIDs	(non-steroidal anti-inflammatory drugs)
ADR	(adverse drug reaction)
HSR	(hypersensitivity reaction)
EHR	(electronic health record)
IgE	(immunoglobulin E)
AERD	(aspirin-exacerbated respiratory disease)
PHS	(Partners HealthCare System)
PEAR	(Partners Enterprise Allergy Repository)
PO	(oral route)
ICD-9	(the International Classification of Diseases, ninth edition)
COX-2	(cyclooxygenase 2)

Highlights Box

1. What is already known about this topic?

Non-steroidal anti-inflammatory drugs (NSAIDs) can cause a variety of adverse drug reactions (ADRs), including side effects as well as allergic or pseudoallergic reactions (hypersensitivity reactions [HSRs]).

2. What does this article add to our knowledge?

1.7% of patients prescribed diclofenac, indomethacin, nabumetone, or piroxicam have ADRs, of which 18.3% are HSRs. Patients with prior HSRs, female sex, autoimmune diseases, and those prescribed a high NSAID dose have an increased risk of NSAIDs HSR.

3. How does this study impact current management guidelines?

Clinician awareness of NSAID hypersensitivity in patients with risk factors can guide patient counseling and safe prescribing practices.

Table I
Incidence of adverse drug reactions and hypersensitivity reactions to prescription NSAIDs (n=62,719)

	Incidence within 1 year n (%)
Adverse Drug Reactions *	1,035 (1.7)
<i>Hypersensitivity Reactions[†]</i>	189 (0.3)
Rash	72 (0.11)
Angioedema or swelling ^{‡§}	51 (0.08)
Urticaria or hives [§]	37 (0.06)
Itching	28 (0.04)
Bronchospasm, wheezing, or shortness of breath	12 (0.02)
Anaphylaxis or hypotension	10 (0.02)
Serum sickness	1 (0.002)
<i>Side Effects[¶]</i>	801 (1.3)
Gastrointestinal upset	543 (0.87)
Dizziness	59 (0.09)
Headache	52 (0.08)
Mental status change	33 (0.05)
Renal toxicity	31 (0.05)
<i>Unknown</i>	55 (0.1)

* Using expanded definition, incidence was 1,156/62,719 (1.8%).

[†] Using expanded definition, incidence was 215/62,719 (0.3%). Numbers sum to >189 because providers can document more than one reaction per drug.

[‡] Includes one patient with diagnosis of chronic idiopathic urticaria/angioedema.

[§] Three patients had both angioedema or swelling and urticaria or hives.

^{||} We show only the five most common side effect reactions.

[¶] Ten patients had both a hypersensitivity reaction and side effect to prescribed NSAID.

Table II
Characteristics of patients prescribed NSAIDs who did and did not develop a hypersensitivity reaction

Patient Characteristics	All (n=62,719)	HSR (n=189)	No HSR (n=62,530)	P Value*
Age, Med [IQR]	52.4 [41.7, 63.2]	51.5 [42.6, 63.9]	52.4 [41.7, 63.2]	0.97
Female Sex	34,784 (55.5)	134 (70.9)	34,650 (55.4)	<0.001
Race/ethnicity				0.07
White	47,247 (75.3)	146 (77.3)	47,101 (75.3)	
Black	4,542 (7.2)	16 (8.5)	4,526 (7.2)	
Hispanic	3,279 (5.2)	4 (2.1)	3,275 (5.2)	
Asian	1,325 (2.1)	5 (2.7)	1,320 (2.1)	
Other	848 (1.4)	6 (3.2)	842 (1.4)	
Unknown	5,478 (8.7)	12 (6.4)	5,466 (8.7)	
Number of Visits, Med [IQR]	6 [3,11]	8 [4,14]	6 [3,11]	<0.001
ADR History				
Prior ADR	19,928 (31.8)	88 (46.6)	19,840 (31.7)	<0.001
Number of Prior ADRs				<0.001
1	11,422 (18.2)	38 (20.1)	11,384 (18.2)	
2 – 5	7,928 (12.6)	38 (20.1)	7,890 (12.6)	
> 5	578 (0.9)	12 (6.4)	566 (0.9)	
Prior NSAID ADR	1,527 (2.4)	10 (5.3)	1,517 (2.4)	0.03
HSR History				
Prior HSRs	9,380 (15.0)	52 (27.5)	9,328 (14.9)	<0.001
Number of Prior HSRs				<0.001
1	6,902 (11.0)	30 (15.9)	6,872 (11.0)	
2 – 5	2,434 (3.9)	18 (9.5)	2,416 (3.9)	
> 5	44 (0.1)	4 (2.1)	40 (0.1)	
Prior NSAID HSR	439 (0.7)	4 (2.1)	435 (0.7)	0.04
NSAID Indications [‡]				
Rheumatoid arthritis	991 (1.6)	7 (3.7)	984 (1.6)	0.03
Joint pain	6,287 (10.0)	30 (15.9)	6,257 (10.0)	0.01
Chronic pain	305 (0.5)	3 (1.6)	302 (0.5)	0.07
Osteoarthritis	4,547 (7.3)	20 (10.6)	4,527 (7.2)	0.09
Gout	3,013 (4.8)	7 (3.7)	3,006 (4.8)	0.61
Pseudogout	83 (0.1)	0 (0)	83 (0.1)	1.00
Back pain	7,194 (11.5)	29 (15.3)	7,165 (11.5)	0.11
Myocarditis/pericarditis	162 (0.3)	0 (0)	162 (0.3)	1.00
Abdominal pain	1,081 (1.7)	3 (1.6)	1,078 (1.7)	1.00
Dysmenorrhea	92 (0.2)	0 (0)	92 (0.2)	1.00
Headache [‡]	2,493 (4.0)	12 (6.4)	2,481 (4.0)	0.09
Acute pain	118 (0.2)	0 (0)	118 (0.2)	1.00

Patient Characteristics	All (n=62,719)	HSR (n=189)	No HSR (n=62,530)	P Value*
General comorbidities [§]				
Autoimmune disease	3,828 (6.1)	22 (11.6)	3,806 (6.1)	0.003
Atopic conditions ^{//}	10,669 (17.0)	39 (20.6)	10,630 (17.0)	0.21
Chronic urticaria/angioedema	227 (0.4)	1 (0.5)	226 (0.4)	0.50
Malignancy [¶]	5,821 (9.3)	14 (7.4)	5,807 (9.3)	0.45
Cardiac conditions	3,521 (5.6)	9 (4.8)	3,512 (5.6)	0.75
Cerebrovascular disease	698 (1.1)	3 (1.6)	695 (1.1)	0.47
Chronic renal impairment	1,027 (1.6)	2 (1.1)	1,025 (1.6)	0.77
NSAID characteristics				
Maximum Dose Prescribed	15,666 (25.0)	60 (31.8)	15,606 (25.0)	0.04
Prior NSAID prescription	26,933 (42.9)	96 (50.8)	26,837 (42.9)	0.03
Number of Prior Prescriptions for NSAIDs				0.001
1	18,089 (28.8)	56 (29.6)	18,033 (28.8)	
2 – 5	8,703 (13.9)	38 (20.1)	8,665 (13.9)	
> 5	141 (0.2)	2 (1.1)	139 (0.2)	
Concomitant Medications ^{***}				
Aspirin	10,854 (17.3)	35 (18.5)	10,819 (17.3)	0.63
Opiate	10,050 (16.0)	37 (19.6)	10,013 (16.0)	0.20
Angiotensin converting enzyme inhibitor	10,923 (17.4)	34 (18.0)	10,889 (17.4)	0.85

* Chi-square test, Fisher's Exact test, Cochran-Armitage Trend test or Wilcoxon Rank Sum test, as indicated.

[†] Problem List entry or ICD-9 code billed within 30 days of NSAID prescription.

[‡] Includes migraine, tension, cluster, post-traumatic, and other (see Table E1 in the Online Repository).

[§] Problem List entry or ICD-9 code billed at any time before NSAID prescription.

^{//} Includes atopic dermatitis, allergic asthma, and allergic rhinitis (see Table E1 in the Online Repository).

[¶] Excluding non-melanomatous skin cancer (see Table E1 in the Online Repository).

^{***} Active EHR prescription at the time of NSAID prescription.

Table III
Summary of multivariable analyses of hypersensitivity reactions to NSAIDs

Factors Associated with Increased Odds of HSR*	Standard HSR Definition		Expanded HSR Definition	
	Odds Ratio [95% CI]	P Value [†]	Odds Ratio [95% CI]	P Value [†]
Prior Drug HSR History	1.8 [1.3, 2.5]	<0.001	1.8 [1.4, 2.5]	<0.001
Female Sex	1.8 [1.3, 2.4]	<0.001	1.7 [1.2, 2.2]	<0.001
Autoimmune disease [‡]	1.7 [1.1, 2.7]	0.02	1.6 [1.1, 2.5]	0.03
Prescribing the Maximum Standing NSAID Dose	1.5 [1.1, 2.0]	0.01	1.3 [1.0, 1.8]	0.07

* Models control for number of patient visits, for standard HSR definition OR 1.0 [95% CI 1.0, 1.0], p=0.02 and for the expanded HSR definition OR 1.0 [95% CI 1.0, 1.0], p=0.004.

[†]Wald Chi-Square

[‡]Patient comorbidity, Problem List entry or ICD-9 code billed at any time before NSAID prescription.